Announcement on Receipt of U.S. FDA Approval for the Subsidiary's Product Eribulin Mesylate Injection
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
(603707)"Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd."Announcement on Receipt of U.S. FDA Approval for the Subsidiary's Product Eribulin Mesylate Injection
Filed with SSE · Stock code 603707 ·
6ix is reading this filing.
View original source (Shanghai Stock Exchange)Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. on 6ix
Story so far
Earlier from Nanjing King-friend Biochemical Pharmaceutical
- Announcement on Obtaining U.S. FDA Approval for Adalimumab Injection of Subsidiary
- Announcement on Obtaining U.S. FDA Approval for Vitamin B1 Injection of Subsidiary
- Announcement on Participation in Subscription of Private Fund Units by Wholly-owned Subsidiary
- Announcement on Subsidiary's Receipt of U.S. FDA Approval for an Additional Manufacturing Site for Amikacin Sulfate Injection
- Announcement on Subsidiary's Receipt of U.S. FDA Approval for an Additional Manufacturing Site for Adalimumab Injection
Follow Nanjing King-friend Biochemical Pharmaceutical into a list and get an email when it puts out news.
Follow Nanjing King-friend Biochemical Pharmaceutical